The Perfect Storm May Be BrewingWe are not granted a "do over" in life very often, however that may be on our horizon. The chance of a trifecta win for Ventripoint has increased in the past month. Three material events that could occur in succession within a short time period could lift our stock price to some blue sky potential that we have all been waiting for these past years. If we receive our second FDA Approval, followed by positive results from the Montefiore Cardiac Readmission Study, then topped off with good actual sales numbers, I feel we will be off to the races. It may be an unpopular viewpoint, however I feel that a Chinese deal that results in dilution at this level and injects the uncertainty of projected sales numbers that we must wait a couple of years to verify, will only stifle the momentum that we would gain from the other three material events. Business dealings in China are very seldom "straight line" and we have no position of strength in negotiating or renegotiating favorable terms at this point in time.